|Over a week ago|
Nektar: Data from study of BEMPEG/nivolumab combo published in Cancer Discovery » 08:4005/2205/22/20
Nektar Therapeutics announced the publication of Phase 1 clinical data for its lead immuno-oncology candidate, bempegaldesleukin in combination with nivolumab, in Cancer Discovery, a journal of the American Association for Cancer Research. Dr. Adi Diab, lead author, Associate Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center noted: "Our data show that BEMPEG, in combination with nivolumab, increases T-cell infiltration into the tumor microenvironment and increases PD-L1 expression on-treatment, leading to very encouraging response rates. Of equal importance, our data did not show an increase in the inflammatory T-cell subtype Th-17, which is known to play a crucial role in mediating the typical checkpoint inhibitor immune-related adverse events. In other words, BEMPEG in combination with nivolumab is well tolerated and induces meaningful tumor and immune responses in solid tumors, such as melanoma, RCC, and NSCLC." Key findings are summarized below: Established the recommended Phase 2 dose of BEMPEG 0.006 mg/kg q3w plus nivolumab 360 mg q3w; AEs were manageable and generally transient and reversible; Combination of BEMPEG plus nivolumab increased absolute numbers and proliferation of CD8+ T- and NK cells in the peripheral blood, and increased expression of genes relating to immune activation in the tumor microenvironment, including the genes encoding the interferon gamma inflammatory response to PD-L1 BEMPEG plus nivolumab demonstrated encouraging ORRs across multiple tumor types, independent of baseline PD-L1 expression. These responses continued to deepen over time; Total ORR was 59.5%, CR was 18.9%, and DCR 83.8%; ORR in PD-L1+ and PD-L1- patients was respectively 64.7% and 50.0%; Among the 22 patients with confirmed objective responses, median TTR was 1.9 months (range 1.3-7.8) and median DOR was not reached.
Nektar price target lowered to $26 from $32 at H.C. Wainwright » 07:0805/1205/12/20
H.C. Wainwright analyst…
H.C. Wainwright analyst Debjit Chattopadhyay lowered the firm's price target on Nektar Therapeutics to $26 from $32 and keeps a Neutral rating on the shares following the company's Q1 results. Nektar's company-sponsored programs moving forward, with modest delays, Chattopadhyay tells investors in a research note.
Nektar CEO: Many of our clinical trial timelines remain intact » 17:2505/0705/07/20
"Amid the challenges…
"Amid the challenges of the evolving COVID-19 pandemic, our Nektar team made significant progress to advance our various clinical studies for our immuno-oncology pipeline while also prioritizing the safety of the patients we serve, our employees and the physicians and staff in our clinical trial network," said Howard W. Robin, President and CEO of Nektar. "For our ongoing studies in oncology, we are working with our global study sites to ensure that patients continue to receive uninterrupted access to study treatment and that we preserve the integrity and conduct of our trials. Many of our clinical trial timelines remain intact; however, at this time, we currently expect that enrollment and study starts managed by our partners will likely be delayed from three to six months. From an operational perspective, Nektar's strong financial position coupled with decisive mitigation actions to address the potential impact to our business, provides a solid foundation for Nektar as we navigate this unprecedented time."
Nektar reports Q1 EPS (78c), consensus (71c) » 17:2305/0705/07/20
Reports Q1 revenue…
Reports Q1 revenue $50.6M, consensus $47.64M. The loss per share for the first quarter includes (25c) loss per share for the impairment charges and additional costs related to the discontinuation of the NKTR-181 program.
|Over a month ago|
Benchmark starts Nektar at Buy, has conviction in bempeg's odds in melanoma » 07:2104/2204/22/20
As previously reported,…
As previously reported, Benchmark analyst Aydin Huseynov initiated coverage of Nektar with a Buy rating and $26 price target. He has conviction that Nektar's main asset, bempeg, has an above-average chance of gaining approval in combination with nivolumab in first-line metastatic melanoma given bempeg's Phase 1/2 complete response rates and ongoing median progression free survival data, the analyst tells investors. He believes the melanoma indication clinical news should drive shareholder value in the short- to mid-term following "a series of alleged deficiencies in clinical development" that drove weakness in Nektar shares over the last 12 months, Huseynov added.
Nektar initiated with a Buy at Benchmark » 06:3804/2204/22/20
Benchmark analyst Aydin…
Benchmark analyst Aydin Huseynov initiated coverage of Nektar with a Buy rating and $26 price target.
Nektar valuation unlikely to be hurt much by COVID-19, says Mizuho » 07:1404/0204/02/20
Mizuho analyst Difei Yang…
Mizuho analyst Difei Yang reiterates a Buy rating on Nektar Therapeutics with a $35 price target after speaking with management to better understand the potential impact from COVID-19. While some delays in trial enrollment and data readouts should be expected, Nektar's remains in a strong financial position, Yang tells investors in a research note. As such, the analyst does not currently anticipate COVID-19 to have a material impact on the valuation of the company.
Nektar upgraded to Neutral from Sell at Goldman Sachs » 05:0903/3003/30/20
Goldman Sachs analyst…
Goldman Sachs analyst Paul Choi upgraded Nektar Therapeutics to Neutral from Sell with a price target of $20, up from $18. While recognizing the potential risk of delays across its clinical programs, the analyst thinks Nektar is well positioned weather the impact from COVID-19. The company has $1.6B in cash and long-term investments, bempeg data in melanoma and lung could come by the end of 2020, and the NKTR-358 lupus data at mid-year should support expansion into additional autoimmune indications, Choi tells investors in a research note.
Nektar trading resumes 09:5103/1203/12/20
Nektar trading halted, volatility trading pause 09:3203/1203/12/20